- Home
- ADPT vs TLRY Comparison
ADPT vs TLRY Comparison
Compare ADPT & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- TLRY
- Stock Information
- Founded
- ADPT 2009
- TLRY N/A
- Country
- ADPT United States
- TLRY Canada
- Employees
- ADPT N/A
- TLRY N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- ADPT Health Care
- TLRY Health Care
- Exchange
- ADPT Nasdaq
- TLRY Nasdaq
- Market Cap
- ADPT 2.0B
- TLRY 1.8B
- IPO Year
- ADPT 2019
- TLRY 2018
- Fundamental
- Price
- ADPT $15.53
- TLRY $1.71
- Analyst Decision
- ADPT Strong Buy
- TLRY Buy
- Analyst Count
- ADPT 10
- TLRY 4
- Target Price
- ADPT $13.60
- TLRY $1.58
- AVG Volume (30 Days)
- ADPT 2.0M
- TLRY 101.6M
- Earning Date
- ADPT 11-06-2025
- TLRY 10-09-2025
- Dividend Yield
- ADPT N/A
- TLRY N/A
- EPS Growth
- ADPT N/A
- TLRY N/A
- EPS
- ADPT N/A
- TLRY N/A
- Revenue
- ADPT $205,216,000.00
- TLRY $830,766,000.00
- Revenue This Year
- ADPT $32.63
- TLRY $6.66
- Revenue Next Year
- ADPT $16.31
- TLRY $4.75
- P/E Ratio
- ADPT N/A
- TLRY N/A
- Revenue Growth
- ADPT 21.60
- TLRY 2.31
- 52 Week Low
- ADPT $4.27
- TLRY $0.35
- 52 Week High
- ADPT $15.94
- TLRY $2.32
- Technical
- Relative Strength Index (RSI)
- ADPT 66.13
- TLRY 57.41
- Support Level
- ADPT $14.11
- TLRY $1.51
- Resistance Level
- ADPT $15.26
- TLRY $2.26
- Average True Range (ATR)
- ADPT 0.73
- TLRY 0.19
- MACD
- ADPT 0.12
- TLRY 0.01
- Stochastic Oscillator
- ADPT 87.90
- TLRY 50.45
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.